Laura Fernández-García

Laura Fernández-García

Auto-generated profile, based on publicly available information

Laura Fernández-García

Grupo de Microbiología Traslacional y Multidisciplinar (MicroTM)-Servicio de Microbiología Instituto de Investigación Biomédica A Coruña (INIBIC); Hospital A Coruña (CHUAC); Universidad de A Coruña (UDC)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
IBInes Bleriot
Ines Bleriot
LBLucía Blasco
Lucía Blasco
OSOlga Pacios Santamaría
Olga Pacios Santamaría
LFLaura Fernández-García
Laura Fernández-García
MLMaria Lopez
Maria Lopez
Maria TomasMaria Tomas
Maria Tomas
Researchers, including microbiologists and infectious disease specialists, require more knowledge about the interactions between phages and their bacterial hosts and about their defense mechanisms. In this study, we analyzed the molecular mechanisms of viral and bacterial defense in phages infecting clinical isolates of K. pneumoniae .

4 March 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
LBLucía Blasco
Lucía Blasco
CIClara Ibarguren-Quiles
Clara Ibarguren-Quiles
CLCarla López-Causape
Carla López-Causape
LALucía Armán
Lucía Armán
ABAntonio Barrio-Pujante
Antonio Barrio-Pujante
Maria TomasMaria Tomas
Maria Tomas
Pseudomonas aeruginosa is a bacterial pathogen that is a major cause of lung infections in cystic fibrosis (CF) and other patients. Isolates of P. aeruginosa from CF patients commonly carry filamentous phages (Pf phages), which constitute a family of temperate phages known to be related to biofilm production and antibiotic sequestration. In this study, we identified 12 new Pf phage genomes in a collection of clinical isolates of P. aeruginosa from CF patients. Study of the anti-phage defense systems in the bacterial isolates revealed the presence of 89 such systems, of which eight were encoded in the Pf phage genomes. Finally, although a weak relation between resistance to phage infection and the number of anti-phage defense systems was detected, it was observed that the phage resistance was related to the presence of Pf phages and the anti-phage defense systems encoded in these phages. IMPORTANCE: Bacteria harbor a wide range of defense mechanisms to avoid phage infections that hamper the application of phage therapy because they can lead to the rapid acquisition of phage resistance. In this study, eight anti-phage defense systems were found in the genome of 12 Pf phages that were presents in 56% of the CF isolates of P. aeruginosa . The high prevalence of these phages underlines the importance of our findings about newly discovered filamentous phages and the role of these phages in resistance to phage infections. Thus, the knowledge of the anti-defense system in the Pf phage genomes could be useful in assessing the possible application of phage therapy to treat an infectious disease.

5 May 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
CIClara Ibarguren-Quiles
Clara Ibarguren-Quiles
LBLucía Blasco
Lucía Blasco
CLCarla López-Causape
Carla López-Causape
IBInes Bleriot
Ines Bleriot
LFLaura Fernández-García
Laura Fernández-García
Maria TomasMaria Tomas
Maria Tomas
The current health crisis caused by multidrug-resistant (MDR) pathogens is one of the health problems of most concern globally. Infections caused by these pathogens, such as Pseudomonas aeruginosa , lead to high rates of complications, particularly in compromised patients such as cystic fibrosis (CF) patients. The need to counteract and minimize the forecast future impact has led to the rescue of phage therapy. The use of bacteriophages has important advantages, including highly specific targeting, self-amplification at the infection site, minimal disruption of the microbiome, safety, and biocompatibility. However, the capacity of bacteria to escape these entities results in a form of resistance that compromises the effectiveness of the therapy. This involves the search for potential alternatives, such as the phage tail-like bacteriocins (PTLBs), also named as tailocins. These high-molecular-weight particles resemble the tail structure of bacteriophages and are characterized by the absence of genetic material, avoiding the development of resistance, one of the major handicaps associated with phage therapy. In this study, we detected 34 different PTLBs in 75 P. aeruginosa genomes, with different serotypes and sequence types, 11 of which were characterized as novel F-type PTLB subtypes (F13–F24). Furthermore, we report that four selected PTLBs (R1, F15, F19, and R3–F24) can deal with bacterial infection, with the R1 and the F15 PTLBs being the most efficient in clearing infection in vitro , yielding a survival rate of more than 75% in the Galleria mellonella larvae in vivo model. This reaffirms the potential of PTLBs to control P. aeruginosa infections, which can cause chronic infections in some patients, such as people with CF, due to its strong impact as a MDR bacterium. IMPORTANCE: The 75 Pseudomonas aeruginosa genomes from people with cystic fibrosis in the study collection included at least one phage tail-like bacteriocins (PTLB) cluster. From the 34 different PTLBs detected in the study collection, 7 were R-type, 10 were complex (R- and F-type encoded), and 14 were F-type PTLBs. Eleven new F-type PTLBs were described in the P. aeruginosa collection under study. An association between the O-antigen present on the surface of the P. aeruginosa isolate and the encoded PTLB subtype was detected. The R1 and F15 PTLB subtypes display high antimicrobial activity both in vitro and in vivo ( Galleria mellonella ).

20 August 2025 in bioRxiv
Verified
Preprint
Open access
CIClara Ibarguren-Quiles
Clara Ibarguren-Quiles
LBLucía Blasco
Lucía Blasco
CLCarla López-Causape
Carla López-Causape
IBInes Bleriot
Ines Bleriot
LFLaura Fernández-García
Laura Fernández-García
Maria TomasMaria Tomas
Maria Tomas
SUMMARY: The current health crisis caused by multidrug resistant (MDR) pathogens is one of the health problems of most concern globally. Infections caused by these pathogens, such as Pseudomonas aeruginosa , lead to high rates of complications, particularly in compromised patients such as cystic fibrosis (CF) patients. The need to counteract and minimize the forecast future impact has led to the rescue of phage therapy. The use of bacteriophages has important advantages, including highly specific targeting, self-amplification at the infection site, minimal disruption of the microbiome, safety and biocompatibility. However, the capacity of bacteria to escape these entities results in a form of resistance that compromises the effectiveness of the therapy. This involves the search for potential alternatives, such as the phage tail-like bacteriocins (PTLBs), also named as tailocins. These high molecular weight particles resemble the tail structure of bacteriophages and are characterized by the absence of genetic material, avoiding the development of resistance, one of the major handicaps associated with phage therapy. In this study, we detected 34 different PTLBs in 75 P. aeruginosa genomes, with different serotypes and sequence types, 11 of which were characterized as novel F-type PTLBs subtypes (F13-F24). Furthermore, we report that four selected PTLBs (R1, F15, F19, R3-F24) can deal with bacterial infection, with the R1 and the F15 PTLBs being the most efficient in clearing infection in vitro , yielding a survival rate of more than 75% in the Galleria mellonella larvae in vivo model. This reaffirms the potential of PTLBs to control P. aeruginosa infections, which can cause chronic infections in some patients, such as people with CF, due to its strong impact as a MDR bacterium. GRAPHICAL HIGHLIGHTS: -The 75 Pseudomonas aeruginosa genomes from people with cystic fibrosis in the study collection included at least one Phage tail-like bacteriocins (PTLB) cluster. -From the 34 different PTLBs detected in the study collection, 7 were R-type, 10 were complex (R and F-type encoded) and 14 were F-type PTLBs. -11 new F-type PTLBs were described in the Pseudomonas aeruginosa collection under study. -An association between the O-antigen present on the surface of the Pseudomonas aeruginosa isolate and the encoded PTLB subtype was detected. -The R1 and F15 PTLBs subtypes display high antimicrobial activity both in vitro and in vivo ( Galleria mellonella ).

30 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
COConcha Ortiz-Cartagena
Concha Ortiz-Cartagena
LFLaura Fernández-García
Laura Fernández-García
LBLucía Blasco
Lucía Blasco
OSOlga Pacios Santamaría
Olga Pacios Santamaría
IBInes Bleriot
Ines Bleriot
Maria TomasMaria Tomas
Maria Tomas
At the end of 2019, the new coronavirus, SARS-CoV-2, began a pandemic that persists to date and which has caused more than 6.2 million deaths. In the last couple of years, researchers have made great efforts to develop a diagnostic technique that maintains high levels of sensitivity and specificity, since an accurate and early diagnosis is required to minimize the prevalence of SARS-CoV-2 infection. In this context, CRISPR-Cas systems are proposed as promising tools for development in diagnostic techniques due to their high specificity, highlighting that Cas13 endonuclease discriminates single nucleotide changes and displays a collateral activity against single stranded RNA molecules. With the aim of improve the sensitivity of the diagnosis, this technology is usually combined with isothermal pre-amplification reactions (SHERLOCK, DETECTR). Basing on this, we have developed an RT-LAMP-CRISPR-Cas13a for SARS-CoV-2 virus detection in nasopharyngeal samples without using RNA extraction kit that exhibited 100 % specificity and 83 % sensitivity, as well as a positive predictive value of 100 % and a negative predictive value of 100%, 81%, 79.1% and 66.7 % in 30 Ct and total Ct values, respectively. Importance During Covid19 crisis has driven the development innovative molecular diagnose including the CRISPR-Cas technology. This work we have performed a protocol working with RNA-extraction kit free samples, places RT-LAMP-CRISPR-Cas13a technology at the top of rapid and specific diagnostic methods for COVID19 due to the high levels of specificity (100%), sensitivity (83%), PPV (100%) and NPV (81% in high loads viral) obtained in clinical samples.

20 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CCConcha Ortiz Cartagena
Concha Ortiz Cartagena
PFPatricia Fernández-Grela
Patricia Fernández-Grela
LALucia Armán
Lucia Armán
CIClara Ibarguren
Clara Ibarguren
LBLucía Blasco
Lucía Blasco
Maria TomasMaria Tomas
Maria Tomas
Antimicrobial resistance (AMR) is an important threat to public health that has led to the development of innovative alternative treatments for bacterial infections, such as phage therapy. However, one of the greatest disadvantages of phage therapy is the generation of phage-resistant bacterial mutants via bacterial defence mechanisms, which are mainly contained in genomic islands (GIs) and controlled by the quorum sensing (QS) network. In this study, 309 pathogenic islands (PAIs) harbouring a total of 22.1 % of proteins related to anti-phage defence (APD) were detected in the genome of 48 K. pneumoniae strains. Several type I and type II CBASS systems were also detected in the genome of the 48 K. pneumoniae strains, but only 2 type II CBASS systems were located in PAIs. We constructed a knockout K. pneumoniae strain, not expressing the cyclase gene from the type II CBASS system present in PAIs, to study the regulatory role of QS in expressing the gene. As the anti-phage CBASS system is an abortive infection (Abi) system, the role of the type II CBASS system in regulating cell viability was assessed. The knockout strain was confirmed by targeting the LAMP-CRISPR-Cas13a technique specifically to the cyclase gene, and the same protocol was also used to detect the gene of the main cyclase in these type I CBASS systems, i.e. APECO1. The study findings demonstrate the regulatory role of the QS network in anti-phage defence systems. Finally, this is the first work which development an innovative biotechnological application for the LAMP-CRISPR-Cas13a rapid-technique (<2 hours) in optimizing phage therapy by detecting bacterial resistance mechanisms, by predicting the potential inefficacy of a therapeutic phage and thus improving patient prognosis.